While the U.S. government has recently licensed monoclonal antibody therapies (LEQEMBI®), anti-amyloid vaccines may offer a convenient, affordable, and accessible means of preventing and treating Alzheimer's Disease (AD).
Polio Vaccine Switch Under Review
The Strategy Committee of the Global Polio Eradication Initiative (GPEI) recently announced it has commissioned a formal evaluation of the 2016 global withdrawal of the Sabin poliovirus 2 (OPV2) vaccine and switch from trivalent oral polio vaccine (tOPV) to bivalent OPV (bOPV).
Confirmed on August 9, 2023, the evaluation aims to generate critical lessons learned from the OPV2 withdrawal to guide the direction of the GPEI (including future OPV withdrawal efforts) and secure a lasting world free of all polioviruses.